Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375645 | 1.00 | ALK (1.00) | ALK | |
| SCHEMBL15375668 | 0.91 | ALK (0.84) | ALK | |
| SCHEMBL15375499 | 0.88 | ALK (1.00) | ALK | |
| SCHEMBL15375501 | 0.88 | ALK (1.00) | ALK | |
| SCHEMBL15375449 | 0.87 | ALK (1.00) | ALK | |
| SCHEMBL15375448 | 0.87 | ALK (1.00) | ALK | |
| SCHEMBL15375477 | 0.87 | ALK (1.00) | ALK | |
| SCHEMBL15375478 | 0.87 | ALK (1.00) | ALK | |
| SCHEMBL15375327 | 0.86 | ALK (1.00) | ALK | |
| SCHEMBL15375326 | 0.86 | ALK (1.00) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855475-B1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-06-28 | — | — | EP | disclosed |
| EP-2855475-B1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-06-28 | — | — | EP | disclosed |
| US-9428500-B2 | Alpha-carbolines for the treatment of cancer | UNIVERSITA DEGLI STUDI DI MILANO—BICOCCA (IT) | 2016-08-30 | — | — | US | disclosed |
| US-9428500-B2 | Alpha-carbolines for the treatment of cancer | UNIVERSITA DEGLI STUDI DI MILANO—BICOCCA (IT) | 2016-08-30 | — | — | US | disclosed |
| US-9428500-B2 | Alpha-carbolines for the treatment of cancer | UNIVERSITA DEGLI STUDI DI MILANO—BICOCCA (IT) | 2016-08-30 | — | — | US | disclosed |
| US-20150105554-A1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2015-04-16 | — | — | US | disclosed |
| US-20150105554-A1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2015-04-16 | — | — | US | disclosed |
| US-20150105554-A1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2015-04-16 | — | — | US | disclosed |
| EP-2662372-A1 | Alpha-carbolines for the treatment of cancer | Università Degli Studi Di Milano - Bicocca (IT) | 2013-11-13 | — | — | EP | disclosed |
| EP-2662372-A1 | Alpha-carbolines for the treatment of cancer | Università Degli Studi Di Milano - Bicocca (IT) | 2013-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105554-A1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | ALK, CSNK1A1, BRAF | ALK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.